- ICH GCP
- US Clinical Trials Registry
- Klinisk forsøg NCT05828511
Et vindue med muligheder for at lære, om Linvoseltamab er sikkert og veltolereret, og hvor godt det virker hos deltagere med nyligt diagnosticeret myelomatose, som ikke allerede har modtaget behandling. (LINKER-MM4)
Fase 1/2 undersøgelse af Linvoseltamab (Anti-BCMA X Anti-CD3 bispecifikt antistof) hos tidligere ubehandlede patienter med symptomatisk myelomatose
This study is researching an experimental drug called linvoseltamab (called "study drug"). The study is focused on participants with newly diagnosed multiple myeloma (NDMM) who are eligible for high dose chemotherapy with autologous stem cell transplantation (transplant-eligible) or ineligible for autologous stem cell transplantation (transplant-ineligible).
The aim of this clinical trial is to study the safety, tolerability (how the body reacts to the drug), and effectiveness (tumor shrinkage) of linvoseltamab in study participants with NDMM as a first step in determining if the study drug has a role in the treatment of NDMM.
This study consists of 2 phases:
- In Phase 1 Parts A and B, the study drug will be given to participants to study the side effects of the study drug and to establish the regimen (initial doses and full dose) of the study drug to be given to participants in Phase 2.
- In Phase 1 Part C, the study drug will be given to participants to study the side effects when using different initial doses of the study drug.
- In Phase 2, the study drug will be given to more participants to continue to assess the side effects of the study drug and to evaluate the activity of the study drug to shrink the tumor (multiple myeloma) in participants with NDMM.
The study is looking at several research questions, including:
- What side effects may happen from taking linvoseltamab?
- What the right dosing regimen is for linvoseltamab?
- How many participants treated with linvoseltamab have improvement of their disease and for how long?
- The effects of linvoseltamab study treatment before and after transplant
- How much linvoseltamab is in the blood at different times?
- Whether the body makes antibodies against linvoseltamab (which could make the drug less effective or could lead to side effects).
Studieoversigt
Status
Betingelser
Intervention / Behandling
Undersøgelsestype
Tilmelding (Faktiske)
Fase
- Fase 2
- Fase 1
Kontakter og lokationer
Studiesteder
-
-
California
-
Los Angeles, California, Forenede Stater, 90095
- University of California Los Angeles (UCLA)
-
Orange, California, Forenede Stater, 92868
- UC Irvine Health
-
-
Colorado
-
Denver, Colorado, Forenede Stater, 80218
- Colorado Blood Cancer Institute/SCRI
-
-
Kentucky
-
Louisville, Kentucky, Forenede Stater, 40207
- Norton Cancer Institute
-
-
Michigan
-
Detroit, Michigan, Forenede Stater, 48201
- Karmanos Cancer Institute
-
-
New Jersey
-
New Brunswick, New Jersey, Forenede Stater, 08901
- Rutgers Cancer Institute of New Jersey
-
-
New York
-
Mineola, New York, Forenede Stater, 11501
- Perlmutter Cancer Center at NYU Langone Hospital - Long Island
-
New York, New York, Forenede Stater, 10016
- Perlmutter Cancer Center
-
New York, New York, Forenede Stater, 10032
- Columbia University _ New York Presbyterian
-
Stony Brook, New York, Forenede Stater, 11794
- Stony Brook University Hospital
-
-
North Carolina
-
Charlotte, North Carolina, Forenede Stater, 28204
- Levine Cancer Institute
-
Durham, North Carolina, Forenede Stater, 27705
- Duke University Health System (DUHS)
-
-
Texas
-
Houston, Texas, Forenede Stater, 77030
- The University of Texas MD Anderson Cancer Center
-
-
-
-
-
Lille, Frankrig, 59000
- CHU De Lille
-
Montpellier, Frankrig, 342950
- Centre Hospitalier Universitaire (CHU) Montpellier
-
Paris, Frankrig, 75010
- Hopital Saint Louis
-
Paris, Frankrig, 75651
- University Hospitals Pitie Salpetriere - Charles Foix
-
-
Vienne
-
Poitiers, Vienne, Frankrig, 86021
- Centre Hospitalier Universitaire (CHU) de Poitiers
-
-
Île-de-France Region
-
Antony, Île-de-France Region, Frankrig, 92160
- Hopital Prive d'Antony
-
Paris, Île-de-France Region, Frankrig, 75015
- Hopital Necker
-
Villejuif, Île-de-France Region, Frankrig, 94800
- Gustave Roussy
-
-
-
-
-
Barcelona, Spanien, 08036
- Hospital Clinic de Barcelona
-
Barcelona, Spanien, 08908
- Institut Catala dOncologia (ICO Hospitalet)
-
Madrid, Spanien, 28027
- Clinica Universidad de Navarra - Madrid
-
Madrid, Spanien, 28006
- Universitary Hospital La Princesa
-
Salamanca, Spanien, 37007
- Hospital Universitario de Salamanca
-
Valencia, Spanien, 46026
- Hospital Universitari i Politecnic La Fe
-
-
Barcelona
-
Badalona, Barcelona, Spanien, 08916
- Hospital Germans Trias i Pujol
-
-
Madrid
-
Pozuelo de Alarcón, Madrid, Spanien, 28223
- Hospital Universitario Quiron Salud Madrid
-
-
Navarre
-
Pamplona, Navarre, Spanien, 31008
- Clinica Universidad de Navarra
-
-
Principality of Asturias
-
Oviedo, Principality of Asturias, Spanien, 33011
- Hospital Universitario Central de Asturias
-
-
Valencia
-
Alicante, Valencia, Spanien, 03010
- Hospital General Universitario Doctor Balmis Alicante
-
-
Deltagelseskriterier
Berettigelseskriterier
Aldre berettiget til at studere
Tager imod sunde frivillige
Køn, der er berettiget til at studere
Beskrivelse
Key Inclusion Criteria:
- Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1, or 2
- Confirmed diagnosis of symptomatic Multiple Myeloma (MM) by International Myeloma Working Group (IMWG) diagnosis criteria, as described in the protocol
- Response-evaluable myeloma, according to the 2016 IMWG response criteria, as defined in the protocol
- No prior therapy for MM, with the exception of prior emergent or palliative radiation and up to 1 month of single-agent corticosteroids, with washout periods as per the protocol
- Participants must have evidence of adequate bone marrow reserves and hepatic, renal and cardiac function as defined in the protocol
- Participants must be age <70 and have adequate hepatic, renal, pulmonary and cardiac function to be considered transplant-eligible. The specific thresholds for adequate organ function are as per institutional guidance.
Key Exclusion Criteria:
- Receiving any concurrent investigational agent with known or suspected activity against MM, or agents targeting the A proliferation-inducing ligand (APRIL)/ Transmembrane activator and calcium modulator and cyclophilin ligand interactor (TACI)/BCMA axis
- Known Central Nervous System (CNS) involvement with MM, known or suspected Progressive Multifocal Leukoencephalopathy (PML), a history of neurocognitive conditions, or CNS movement disorder, or history of seizure within 12 months prior to study enrollment
- Rapidly progressive symptomatic disease, (e.g. progressing renal failure or hypercalcemia not responsive to standard medical interventions), in urgent need of treatment with chemotherapy
- Diagnosis of non-secretory MM, active plasma cell leukemia primary light-chain (AL) amyloidosis, Waldenström macroglobulinemia (lymphoplasmacytic lymphoma), or known POEMS syndrome (Plasma cell dyscrasia with polyneuropathy, Organomegaly, Endocrinopathy, Monoclonal protein, and Skin changes)
Note: Other protocol-defined Inclusion/Exclusion criteria apply
Studieplan
Hvordan er undersøgelsen tilrettelagt?
Design detaljer
- Primært formål: Behandling
- Tildeling: Ikke-randomiseret
- Interventionel model: Sekventiel tildeling
- Maskning: Ingen (Åben etiket)
Våben og indgreb
Deltagergruppe / Arm |
Intervention / Behandling |
|---|---|
|
Eksperimentel: Phase 1 cohorts
Linvoseltamab dose escalation (part A), dose expansion (part B), and evaluation of alternative step-up regimen (part C) for participants with NDMM who are treatment-naïve. |
Linvoseltamab will be administered by intravenous (IV) infusion
Andre navne:
|
|
Eksperimentel: Phase 2 - transplant ineligible cohort
Transplant-ineligible participants, enrolled in dose expansion, will receive selected linvoseltamab regimen until disease progression as per protocol. |
Linvoseltamab will be administered by intravenous (IV) infusion
Andre navne:
|
|
Eksperimentel: Phase 2 - transplant eligible cohort
Transplant-eligible participants, enrolled in dose expansion, will receive selected linvoseltamab regimen for a fixed duration of treatment as per protocol |
Linvoseltamab will be administered by intravenous (IV) infusion
Andre navne:
|
Hvad måler undersøgelsen?
Primære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Incidence of Dose-Limiting Toxicities (DLTs)
Tidsramme: End of the Observation period; up to day 28
|
Phase 1 |
End of the Observation period; up to day 28
|
|
Incidence of Treatment-Emergent Adverse Events (TEAEs)
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 1 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
Severity of TEAEs
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 1 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
Incidence of Adverse Events of Special Interest (AESIs)
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 1 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
Severity of AESIs
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 1 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
Proportion of participants with a Very Good Partial Response (VGPR) or better using the International Myeloma Working Group (IMWG) response criteria
Tidsramme: Up to 5 years
|
Phase 2 |
Up to 5 years
|
|
Proportion of participants achieving Minimal Residual Disease (MRD) negative status (at 10^-5) after induction with consolidation therapy
Tidsramme: Up to 5 years
|
Phase 2 Transplant-eligible cohort |
Up to 5 years
|
|
Proportion of participants achieving MRD-negative status (at 10^-5) after induction without consolidation therapy
Tidsramme: Up to 5 years
|
Phase 2 Transplant-eligible cohort |
Up to 5 years
|
|
Proportion of participants achieving MRD-negative status as their best response after treatment period I with continuing to treatment period II
Tidsramme: Up to 5 years
|
Phase 2 Transplant-ineligible cohort |
Up to 5 years
|
|
Proportion of participants achieving MRD-negative status as their best response after treatment period I without continuing to treatment period II
Tidsramme: Up to 5 years
|
Phase 2 Transplant ineligible cohort |
Up to 5 years
|
Sekundære resultatmål
Resultatmål |
Foranstaltningsbeskrivelse |
Tidsramme |
|---|---|---|
|
Concentrations of Linvoseltamab in serum
Tidsramme: Post-Last Linvoseltamab Dose, up to 12 weeks
|
Phases 1 and 2 |
Post-Last Linvoseltamab Dose, up to 12 weeks
|
|
Concentrations of total soluble B-Cell Maturation Antigen (BCMA)
Tidsramme: Post-Last Linvoseltamab Dose, up to 12 weeks
|
Phases 1 and 2 |
Post-Last Linvoseltamab Dose, up to 12 weeks
|
|
Incidence of Anti-Drug Antibodies (ADAs) to Linvoseltamab
Tidsramme: Post-Last Linvoseltamab Dose, up to 30 days
|
Phases 1 and 2 |
Post-Last Linvoseltamab Dose, up to 30 days
|
|
Magnitude of ADAs to Linvoseltamab
Tidsramme: Post-Last Linvoseltamab Dose, up to 30 days
|
Phases 1 and 2 |
Post-Last Linvoseltamab Dose, up to 30 days
|
|
Objective Response Rate (ORR) measured using the IMWG criteria
Tidsramme: Up to 5 years
|
Phase 1 |
Up to 5 years
|
|
Duration Of Response (DOR) measured using the IMWG criteria
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 1 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
Progression-Free Survival (PFS) measured using the IMWG criteria
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 1 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
Proportion of participants achieving MRD-negative status (at 10^-5) in participants with NDMM measured using the IMWG criteria
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 1 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
Incidence of TEAEs
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
Severity of TEAEs
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
Incidence of AESIs
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
Severity of AESIs
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
ORR of participants deemed transplant-eligible and transplant-ineligible by the treating physician
Tidsramme: Up to 5 years
|
Phase 2 |
Up to 5 years
|
|
MRD-negative status of participants deemed transplant-eligible and transplant-ineligible by the treating physician
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
DOR of participants deemed transplant-eligible and transplant-ineligible by the treating physician
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
PFS of participants deemed transplant-eligible and transplant-ineligible by the treating physician
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
Overall Survival (OS) of participants deemed transplant-eligible and transplant-ineligible by the treating physician
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
Time To Response (TTR) as measured using the IMWG criteria
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
ORR by risk levels
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
MRD-negative status by risk levels
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
DOR by risk levels
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
TTR by risk levels
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
PFS by risk levels
Tidsramme: Post-Last Linvoseltamab Dose, up to 90 days
|
Phase 2 |
Post-Last Linvoseltamab Dose, up to 90 days
|
|
Incidence of MRD-negative status
Tidsramme: Up to 5 years
|
Phase 2 |
Up to 5 years
|
|
Cluster of Differentiation 34+ (CD34+) stem cell yield
Tidsramme: At cycle 4 of induction (each cycle is 28 days long)
|
Phase 2 Transplant-eligible cohort |
At cycle 4 of induction (each cycle is 28 days long)
|
|
Time to neutrophil engraftment
Tidsramme: Up to 100 days post-transplant
|
Phase 2 Transplant-eligible cohort |
Up to 100 days post-transplant
|
|
Time to platelet engraftment
Tidsramme: Up to 100 days post-transplant
|
Phase 2 Transplant-eligible cohort |
Up to 100 days post-transplant
|
|
PFS after ASCT followed by 3 cycles of linvoseltamab
Tidsramme: Up to 5 years
|
Phase 2 Transplant-eligible cohort |
Up to 5 years
|
Samarbejdspartnere og efterforskere
Sponsor
Efterforskere
- Studieleder: Clinical Trial Management, Regeneron Pharmaceuticals
Datoer for undersøgelser
Studer store datoer
Studiestart (Faktiske)
Primær færdiggørelse (Anslået)
Studieafslutning (Anslået)
Datoer for studieregistrering
Først indsendt
Først indsendt, der opfyldte QC-kriterier
Først opslået (Faktiske)
Opdateringer af undersøgelsesjournaler
Sidste opdatering sendt (Faktiske)
Sidste opdatering indsendt, der opfyldte kvalitetskontrolkriterier
Sidst verificeret
Mere information
Begreber relateret til denne undersøgelse
Nøgleord
Yderligere relevante MeSH-vilkår
- Karsygdomme
- Hjerte-kar-sygdomme
- Neoplasmer
- Sygdomme i immunsystemet
- Neoplasmer efter histologisk type
- Hæmatologiske sygdomme
- Lymfoproliferative lidelser
- Immunproliferative lidelser
- Neoplasmer, Plasmacelle
- Hæmostatiske lidelser
- Paraproteinæmier
- Blodproteinforstyrrelser
- Hæmoragiske lidelser
- Hemiske og lymfatiske sygdomme
- Myelomatose
Andre undersøgelses-id-numre
- R5458-ONC-2158
- 2022-500800-24-00 (Ctis)
Plan for individuelle deltagerdata (IPD)
Planlægger du at dele individuelle deltagerdata (IPD)?
IPD-planbeskrivelse
All Individual Patient Data (IPD) that underlie publicly available results will be considered for sharing
IPD-delingstidsramme
When Regeneron has:
- received marketing authorization from major health authorities (e.g., FDA, European Medicines Agency (EMA), Pharmaceuticals and Medical Devices Agency (PMDA), etc.) for the product and indication or has globally discontinued development of the product for all indications on or after April 2020 and has no plans for future development
- made the study results publicly available (e.g., scientific publication, scientific conference, clinical trial registry)
- the legal authority to share the data, and
- ensured the ability to protect participant privacy
IPD-delingsadgangskriterier
Qualified researchers can submit a proposal for access to individual patient or aggregate level data from a Regeneron-sponsored clinical trial through Vivli. Regeneron's Independent Research Request Evaluation Criteria can be found at: https://www.regeneron.com/sites/default/files/Regeneron-External-Data-Sharing-Policy-and-Independent-Research-Request-Evaluation-Criteria.pdf
IPD-deling Understøttende informationstype
- STUDY_PROTOCOL
- SAP
- ICF
- ANALYTIC_CODE
- CSR
Lægemiddel- og udstyrsoplysninger, undersøgelsesdokumenter
Studerer et amerikansk FDA-reguleret lægemiddelprodukt
Studerer et amerikansk FDA-reguleret enhedsprodukt
Disse oplysninger blev hentet direkte fra webstedet clinicaltrials.gov uden ændringer. Hvis du har nogen anmodninger om at ændre, fjerne eller opdatere dine undersøgelsesoplysninger, bedes du kontakte register@clinicaltrials.gov. Så snart en ændring er implementeret på clinicaltrials.gov, vil denne også blive opdateret automatisk på vores hjemmeside .